Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extranodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA
6
We tested a regimen of PEMD (pegaspargase, etoposide, methotrexate and dexamethasone) in 32 newly diagnosed advanced-stage subjects with ENKTL.
Thirty-two consecutive subjects with newly diagnosed advanced-stage (stages III-IV) ENKTL were prospectively studied from July 2010 to December 2015. The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University. Subjects (32 patients) gave written informed consent in accordance with the Declaration of Helsinki. Biopsies were reviewed by ⩾ 2 experienced pathologists and diagnosis was based on WHO criteria. 1 Baseline clinical variables including age, sex, Ann Arbor stage, serum lactate dehydrogenase, blood Epstein-Barr virus (EBV)-DNA levels (EBV-DNA copy number in whole blood was quantified by a real-time PCR based on the amplification of EBNA1 gene with the cut-off value of 5000 copies/ ml), B-symptoms, extra-nodal sites of disease, Eastern Cooperative Oncology Group (ECOG) performance score, bone marrow involvement, distant lymph-node involvement, International Prognostic Index (IPI) scores and prognostic index of natural killer lymphoma (PINK). 9 pegaspargase, etoposide, methotrexate and dexamethasone was given as follows: methotrexate, 3.0 g/m 2 i.v. over 6 h on day 1; etoposide, 100 mg/m 2 i.v. on days 2-4; dexamethasone, 40 mg i.v. on days 1-4; pegaspargase, 2500 U/m 2 i.m. on day 2. Subjects received 4-6 cycles of PEMD every 3 weeks. Patients could receive autologous or allogeneic hematopoietic stem cell transplantation after achieving complete remission or partial remission. The decision was made according to the discretion of the treating physician, mainly on the basis of the patient's age, comorbidities, economy and wishes.
Response criteria are reported using standard criteria. 10 Subjects were evaluated after three cycles of PEMD, after completing PEMD and every 3 months for 2 years thereafter. Responses were classified as complete response (CR), unconfirmed CR (CRu), partial response (PR), stable disease (SD) and progressive disease (PD). Physical exam and laboratory tests were used to evaluate adverse reactions and toxicities. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0.
Primary co-endpoints were response and survival. Overall response rate (ORR) was defined as the rate of CR/CRu and PR. Progression-free survival (PFS) was defined as the interval from study-entry to first progression. OS was defined as interval from study-entry to death from any cause. Secondary endpoints were proportion of subjects completing planned therapy (4-6 cycles of PEMD regimen) and frequencies of adverse events. Follow-up was through August 2016. Kaplan-Meier method was used to calculate PFS and OS. The log-rank test was used to analyze survival differences between the cohorts. Statistical analyses were performed using MedCalc for Windows, version 12.0.4.0 (MedCalc Software, Mariakerke, Belgium). P-values o 0.05 were considered significant.
Baseline variables are indicated in Table 1 . Median age was 48 years (range, 17-73 years). There were 25 males (78%). Nine subjects (28%) had non-nasal NK/T-cell lymphoma including five skin involvement, one testis involvement, one muscle involvement and two gastrointestinal tract involvement. Fourteen subjects (44%) had elevated serum lactate dehydrogenase levels. Thirteen subjects (41%) had higher level of EBV-DNA in whole blood (45000 copies/ml). Ten patients (31%) had distant lymph-node involvement. Twenty-three subjects (72%) had B-symptoms and 17 (53%) had an IPI score ⩾ 3. Nineteen patients (59%) had a PINK score ⩾ 2.
Subjects received a median of four courses of PEMD (range, 1-6). Median follow-up is 48 months (range, 13-74 months). Only four patients had autologous HSCT. Three patients (two with nonnasal type received only one cycle and one with nasal type received two cycles) had early death (within 3 months after the diagnosis) due to haemo-phagocytic lympho-histiocytosis. Five patients (four with nasal type and one with non-nasal type) had disease progression after three cycles of PEMD. In summary, ORR was 75% (95% CI 57-89%) in the 32 subjects with advanced-stage disease including CR/CRu in 15 (47% (95% CI 29-65%)) and a PR in 9 (28% (14-47%)). For all the 32 patients, 4-year PFS was 44% (95% CI 25-63%) and OS 51% (95% CI 32-70%). Table 2 lists grade-3/4 adverse events. Hematologic adverse events occurred in all subjects. Grade-1/2 hypo-fibrinogenemia was observed in 90% of subjects. Hematologic grade-3 toxicities included leukopenia (N = 8), neutropenia (N = 8), anemia (N = 2) and thrombocytopenia (N = 2). The most common nonhematologic grade-3 toxicities were hypo-fibrinogenemia (N = 3) and infection (N = 3). Hematologic grade-4 toxicities included leukopenia (N = 3), neutropenia (N = 3), anemia (N = 1) and thrombocytopenia (N = 1). Non-hematologic grade-4 toxicities included hypo-fibrinogenemia (N = 1), infection (N = 2) and hyper-bilirubinemia (N = 1). There were no treatment-related deaths.
In order to select prognostic variables for advanced-stage ENKTL patients who were given PEMD regimen, univariate and multivariate cox regression analysis were conducted for both PFS and OS. By univariable analysis, factors predictive of both OS and PFS included PINK score above 1, IPI score above 2, elevated lactate dehydrogenase level and EBV-DNA-positivity. Factors significantly associated with PFS and OS in univariate analysis were entered into multivariate analysis. EBV-DNA-positivity and PINK score above 1 remained significant for PFS (HR, 5.19, 95% CI: 1.73-15.52, P o 0.01 and HR, 5.60, 95% CI: 1.46-21.54, P = 0.01) and OS (HR, 6.97, 95% CI: 2.05-23.63, P o 0.01and HR, 4.56, 95% CI: 1.12-18.50, P = 0.03) while IPI score above 2 only had significant trend for OS (HR, 5.02, 95% CI: 0.95-26.5, P = 0.06), not for PFS (HR, 1.77, 95% CI: 0.48-6.54, P = 0.39) ( Table 3) .
Among all the 32 patients, four patients (patients 1-4) experienced early death. Therefore, no dynamic quantitative changes in EBV-DNA with therapy were observed for these four patients. The dynamic continuous quantitative changes of all the other 10 pretreatment EBV-DNA-positive and all 18 EBV-DNAnegative patients with therapy, which were classified as CR/CRu, PR and no response (NR, included SD and PD), were shown in Figure 1 . The three pretreatment EBV-DNA-positive patients (patients 4-6) who experienced PD at the mid-therapy had reelevated EBV-DNA levels ( Figure 1a) . Among the seven pretreatment EBV-DNA-positive patients who achieved more than PR at the end of the therapy, three patients who experienced PD after the completion of the PEMD regimen also had re-elevated EBV-DNA levels (Figure 1b) . One patient (patient 16) had re-elevated EBV-DNA levels among the two EBV-DNA-negative patients (patients 15 and 16) who had PD at the mid-therapy (Figure 1c) . Among the 16 EBV-DNA-negative patients who achieved more than PR at the end of the therapy, two patients (patients 20 and 21) who experienced PD after the completion of the PEMD regimen also had re-elevated EBV-DNA levels (Figure 1d ).
There is no standard therapy for ENKTL. Most data are from retrospective analyses and small prospective series. Anthracyclinecontaining regimens have response rates of 40-60% with high subsequent failure rates.
11 SMILE is the most studied protocol for advanced disease. In a phase-2 study in 20 subjects with advanced disease ORR was 80% (95% CI 56-94%) and 2-year PFS and OS about 45%. 7 However, the significant toxicities that grade-4 neutropenia were occurred in 92% patients and serious infections Non-hematologic Hypo-fibrinogenemia 3 (9%) 1 (3%) 4 (13%) Hypo-albuminemia 2 (6%) 0 (0%) 2 (6%) Hyper-bilirubinemia 2 (6%) 1 (3%) 3 (9%) Aspartate transaminase increase 0 (0%) 0 (0%) 0 (0%) Alanine transaminase increase 0 (0%) 0 (0%) 0 (0%) Infection 3 (9%) 2 (6%) 5 (15%) Appetite loss 1(3%) 0 (0%) 1 (3%) Nausea 0 (0%) 0 (0%) 0 (0%) Diarrhea 0 (0%) 0 (0%) 0 (0%) Vomiting 0 (0%) 0 (0%) 0 (0%) Letter to the Editor were occurred in 31% patients limited the application of this regimen in those not well-fit patients. In our study, the 32 subjects with advanced disease had an ORR rate of (75% (95% CI 57-89%)) which was similar to that of SMILE. 7, 12 Four-year PFS was 44% (95% CI 25-63%) and OS 51% (95% CI 32-70%), results similar to SMILE. 7, 11 PEMD appeared better tolerated than SMILE with 57% (44, 70%) grade-3/-4 neutropenia (P o 0.001) and 21% (11, 33%) grade-3/-4 infection (P o 0.001). The decreased toxicity of PEMD likely results from deleting ifosfamide and using pegaspargase instead of L-asparaginase.
Circulating EBV-DNA in blood is derived from necrotic or apoptotic tumor cells, and thus viral DNA in the whole blood or plasma is strongly associated with survivals and treatment outcomes in patients with ENKTL which have been confirmed in many studies. 9, 13, 14 Similar results were also observed in the present study specially for advanced ENKTL patients who were treated with PEMD regimens. Furthermore, the amount of circulating viral DNA might show the burden and replication of tumors, and it might be undetectable in patients with small tumor burdens or those in whom proliferation is less active. Therefore, the dynamic quantitative changes in EBV-DNA with therapy were also observed in the present study. Patients who experienced PD always had re-elevated EBV-DNA levels in the blood. Therefore, circulating EBV-DNA level was an important prognostic and monitoring tumor markers, which has been added in the prognostic index for natural killer lymphoma (PINK-E) reported by Kim et al. 9 In conclusion, PEMD is safe and effective in persons with newly diagnosed advanced-stage ENKTL, especially for those not well-fit patients. Circulating EBV-DNA levels is an important prognostic and monitoring marker for advanced-stage ENKTL patients who treated with PEMD regimen. Larger prospective studies are needed to more precisely define toxicities and estimate efficacy and to compare PEMD with other regimens. 
